Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.

作者信息

Zaidi Syeda Dua E Zehra, Fatima Zaidi Syeda Mahrukh, Rangwala Burhanuddin Sohail

机构信息

Jinnah Sindh Medical University, Karachi, Pakistan.

Dow University of Health Sciences, Karachi, Pakistan.

出版信息

Ann Hematol. 2024 Jun;103(6):2163-2164. doi: 10.1007/s00277-024-05748-2. Epub 2024 Apr 23.

DOI:10.1007/s00277-024-05748-2

PMID:38652243

Abstract

摘要

相似文献

[1]

Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.

Ann Hematol. 2024-6

[2]

Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.

Ann Hematol. 2024-4

[3]

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Leuk Res. 2018-5

[4]

Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.

Br J Haematol. 2002-7

[5]

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.

Hematol Oncol. 2015-6

[6]

[Myelodysplastic syndromes (MDS) and their evolution].

Rinsho Ketsueki. 1987-8

[7]

[Treatment of myelodysplastic syndromes with immunosuppressive agents].

Rinsho Ketsueki. 2002-4

[8]

Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.

Leuk Res. 2009-9

[9]

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.

Blood. 2003-1-15

[10]

Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?

Haematologica. 2000-9

本文引用的文献

[1]

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.

Cancers (Basel). 2020-12-8

[2]

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy.

Cancers (Basel). 2020-10-26

[3]

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Leuk Res. 2018-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Letter to Editor: Treatment with the apoptosis inhibitor asunercept reduces clone sizes in patients with lower risk myelodysplastic neoplasms.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献